Skip to content
OpenCapital
Get started

Cumberland Pharmaceuticals CPIX Vaprisol — Revenues, including adjustments

Similar metrics at other companies

Alkermes logo
ALKSVivitrol — Revenue
$112.43M+11.3%
Johnson & Johnson logo
JNJSPRAVATO — Sales to customers (Note 9)
$468M+46.3%
HWK
HWKNPharmaceutical — Revenue
$8.32M+15.1%
Bristol-Myers Squibb logo
BMYGross product sales — Total Revenues
$16.93B-14.8%
Esperion Therapeutics logo
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%
Regeneron Pharmaceuticals logo
REGNProduct — Revenue
$1.53B+8.4%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+138%
Enterprise value$90.91M+207%
P/S2.3×+1.3×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%—

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept cpix:RevenueFromContractWithCustomerExcludingAssessedTaxIncludingAdjustments.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's vaprisol — revenues, including adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's vaprisol — revenues, including adjustments?
Cumberland Pharmaceuticals (CPIX) reported vaprisol — revenues, including adjustments of $517 in Q1 2026.
How has Cumberland Pharmaceuticals's vaprisol — revenues, including adjustments changed year-over-year?
Cumberland Pharmaceuticals's vaprisol — revenues, including adjustments increased by 186.2% year-over-year, from -$600 to $517.
What does vaprisol — revenues, including adjustments mean?
This metric represents the gross revenue generated from the specific pharmaceutical product line, inclusive of all sales adjustments such as returns, rebates, and allowances. It serves as a measure of the total market demand and gross commercial performance for the product before accounting for net realization. Monitoring this figure helps assess the impact of pricing strategies and contractual obligations on top-line performance.